Assertio Holdings Oma pääoma 2024

Mitä Assertio Holdings tekee?

Assertio Holdings Inc is a pharmaceutical company based in the USA that specializes in the development and marketing of prescription drugs in various therapeutic areas. The company's history dates back to its founding in 1995 under the name "DepoMed Inc". Since then, the company has undergone numerous changes and restructurings before eventually being renamed Assertio Holdings Inc. The business model of Assertio Holdings Inc focuses on the development and marketing of prescription drugs in areas such as pain management, neurological disorders, complex regional pain syndrome (CRPS), and migraines. An important aspect of Assertio Holdings Inc's business model is its commitment to improving the quality of life for patients affected by these conditions. The company operates several divisions specializing in different therapeutic areas. The three main divisions are: 1. Pain Management: This division focuses on the development and marketing of prescription drugs for pain relief, including opioid-containing medications. Some of the well-known products in this division include the pain medication Gralise and the Fentanyl transdermal patch. 2. Neurology: This division specializes in the development and marketing of prescription drugs for the treatment of neurological disorders such as Parkinson's disease and restless legs syndrome. Some of the well-known products in this division include the Parkinson's medication Rytary and the restless legs syndrome medication Neupro. 3. Hospital: This division focuses on the development and marketing of drugs for the treatment of diseases that typically require hospitalization, such as infections and postoperative pain. Some of the well-known products in this division include the antibiotic Zipsor and the postoperative pain medication Nucynta ER. In addition to these three main divisions, Assertio Holdings Inc also operates a smaller division called "Other." This division includes products that do not fit into the other divisions, such as the migraine medication Cambia. Overall, Assertio Holdings Inc offers a wide range of prescription drugs aimed at improving the quality of life for patients suffering from various conditions. However, in recent years, the company has had to overcome various economic challenges. In 2016, the company was accused of making false claims through the marketing of an opioid called Nucynta. As part of a settlement with the government, the company agreed to pay $35 million and commit to reforms in the marketing of Nucynta. Assertio Holdings Inc also faces a shrinking market for painkillers as the US government and public opinion grow increasingly concerned about the opioid epidemic. In response, the company has realigned its pain management division and increased its investments in novel, opioid-free pain medications. Despite these challenges, Assertio Holdings Inc continues to work on the development and marketing of prescription drugs that can play an important role in improving the health and well-being of patients. Assertio Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.